Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.
Steven Yip(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Ravindran Kanesvaran(University of Ioannina), Ajjai Alva(Michigan Medicine), James Brugarolas(The University of Texas Southwestern Medical Center), Toni K. Choueiri(Harvard University), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), José Manuel Ruiz Morales(Hospital Médica Sur), Anna Paola Fraccon, Konstantinos Koutsoukos(Therapeutics Clinical Research), Jennifer J. Knox(National Cancer Center), Carmel Pezaro(Royal Marsden NHS Foundation Trust), Simon Fu(BC Cancer Agency), Umberto Basso(Istituto Oncologico Veneto), Christian Kollmannsberger(BC Cancer Agency), Takeshi Yuasa(Japanese Foundation For Cancer Research), Jae‐Lyun Lee(Ulsan College), Brian I. Rini(Vanderbilt University Medical Center)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k